BioGaia AB (publ) (FRA:BGLA)

Market Cap	1.07B +19.5%
Revenue (ttm)	142.75M +9.8%
Net Income	31.36M +21.1%
EPS	0.31 +21.3%
Shares Out	n/a
PE Ratio	34.18
Forward PE	27.52
Dividend	0.37 (3.56%)
Ex-Dividend Date	May 8, 2026

Volume	n/a
Open	10.61
Previous Close	10.53
Day's Range	10.61 - 10.61
52-Week Range	8.72 - 12.32
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 12, 2027

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 251
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BGLA

Financial Performance

In 2025, BioGaia AB's revenue was 1.54 billion, an increase of 8.11% compared to the previous year's 1.42 billion. Earnings were 332.76 million, a decrease of -5.30%.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error